On 9/3/25, Avalo Therapeutics Inc (NASDAQ: AVTX) stock enjoyed a major increase of 17.0%, closing at $10.56. Moreover, trading volume in this advance was exceptionally high at 270% of normal. Relative to the market the stock has been weak over the last nine months but has risen 12.3% during the last week.
Current PriceTarget Research Rating
Avalo Therapeutics has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Avalo Therapeutics has a good Appreciation Score of 82 but a very low Power Rating of 5, and the Low Neutral Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment